JP2019512507A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512507A5
JP2019512507A5 JP2018549168A JP2018549168A JP2019512507A5 JP 2019512507 A5 JP2019512507 A5 JP 2019512507A5 JP 2018549168 A JP2018549168 A JP 2018549168A JP 2018549168 A JP2018549168 A JP 2018549168A JP 2019512507 A5 JP2019512507 A5 JP 2019512507A5
Authority
JP
Japan
Prior art keywords
composition
agonist
subject
gemfibrozil
pparα
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018549168A
Other languages
English (en)
Japanese (ja)
Other versions
JP7012658B2 (ja
JP2019512507A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021799 external-priority patent/WO2017160629A1/en
Publication of JP2019512507A publication Critical patent/JP2019512507A/ja
Publication of JP2019512507A5 publication Critical patent/JP2019512507A5/ja
Application granted granted Critical
Publication of JP7012658B2 publication Critical patent/JP7012658B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018549168A 2016-03-15 2017-03-10 アミロイドβタンパク質の排出を刺激する組成物及び方法 Active JP7012658B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662308374P 2016-03-15 2016-03-15
US62/308,374 2016-03-15
PCT/US2017/021799 WO2017160629A1 (en) 2016-03-15 2017-03-10 COMPOSITION AND METHODS FOR STIMULATING CLEARANCE OF AMYLOID-β PROTEIN

Publications (3)

Publication Number Publication Date
JP2019512507A JP2019512507A (ja) 2019-05-16
JP2019512507A5 true JP2019512507A5 (enExample) 2020-04-23
JP7012658B2 JP7012658B2 (ja) 2022-02-14

Family

ID=59852353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018549168A Active JP7012658B2 (ja) 2016-03-15 2017-03-10 アミロイドβタンパク質の排出を刺激する組成物及び方法

Country Status (5)

Country Link
US (2) US11135180B2 (enExample)
EP (1) EP3429671B1 (enExample)
JP (1) JP7012658B2 (enExample)
CA (1) CA3017760A1 (enExample)
WO (1) WO2017160629A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111084768A (zh) * 2018-10-24 2020-05-01 中国科学院昆明动物研究所 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途
JP2022541021A (ja) * 2019-07-16 2022-09-21 ラッシュ・ユニバーシティ・メディカル・センター 神経変性障害を治療するためのベンゾエート含有組成物の使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392287B8 (en) * 2001-05-25 2007-01-10 Schering Corporation Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US9750712B2 (en) * 2012-12-07 2017-09-05 Rush University Medical Center Composition and method for treating neuronal ceroid lipofuscinosis
US20150320706A1 (en) * 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
WO2016201086A1 (en) * 2015-06-12 2016-12-15 Rush University Medical Center Compositions and methods for stimulating adam10-mediated nonamyloidogenic proteolysis of amyloid precursor protein

Similar Documents

Publication Publication Date Title
Castro et al. Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) rat model of Parkinson's disease
Imbimbo et al. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?
Sprenger et al. Management of motor and non-motor symptoms in Parkinson’s disease
Jin et al. Minocycline improves postoperative cognitive impairment in aged mice by inhibiting astrocytic activation
Rascol et al. Long-term treatment of Parkinson's disease with bromocriptine.
JP2016540785A5 (enExample)
Fidalgo et al. Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson’s disease
JP2020534270A5 (enExample)
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
JP2018509388A5 (enExample)
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
AU2015358512B2 (en) Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
JP2019512507A5 (enExample)
JP2013520448A5 (enExample)
RU2008134143A (ru) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения
JP2016505050A5 (enExample)
CO6400019A1 (es) Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion
AU2016228771A1 (en) Conformationally stable analogs of the response selective C5a agonist EP67
JP2018505901A5 (enExample)
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
Mostofsky et al. The control of blepharospasm by essential fatty acids
JP2014509656A5 (enExample)
US20250360215A1 (en) Pharmaceutical combinations and methods for preventing or treating neurodegenerative diseases
JP2010539242A5 (enExample)